Modulation of alloreactivity using genetically modified T lymphocytes;Modulation de l'alloreactivite par l'utilisation de lymphocytes T genetiquement modifies

Transfusion Clinique et Biologique

Volumn 4, Issue 3, 1997, Pages 275-280

  Tiberghien, P ^a  

^a Etablissement Transfus Franche C   (France)

Author keywords

alloreactivity; ganciclovir; gene therapy; suicide gene

Indexed keywords

GANCICLOVIR; HERPES SIMPLEX THYMIDINE KINASE; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; THYMIDINE KINASE;

ALLOGRAFT; CLINICAL TRIAL; CONFERENCE PAPER; GENE THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; SUICIDE GENE; T LYMPHOCYTE; VIRUS INFECTION; ENZYMOLOGY; FEMALE; GENE TRANSFER; GENETICS; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX VIRUS 1; IMMUNOLOGY; MALE; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; FEMALE; GENE TRANSFER TECHNIQUES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MEMBRANE PROTEINS; T-LYMPHOCYTES; THYMIDINE KINASE;

EID: 0030623394     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1246-7820(97)80052-3     Document Type: Conference Paper

References (32)

1. Burakoff SJ, Degg HJ, Ferrara J, Atkinson F. Graft versus-Host Disease: Immunology, pathophysiology and treatment. In: Hematology, Marcel Dekker, New York, 1990.
2. Horrowitz MM, Gale RP, Sondel PM, Golman JM, Kersey J, Kolb HJ et al. Graft versus leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Antin JH. Graft versus leukemia: non longer an epiphenomenon. Blood 1993; 82: 2273-2277.
4. Blaise D, Gravis G, Maraninchi D. Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet 1994; 341: 51-52.
5. Marmont AM, Horowitz MM, Gale RP, Sobocinski K, Ash RC, Bekkum DWV et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
6. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med, 1986; 314: 729-735.
7. Kernan NA, Barsch G, Ash DC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593-602.
8. Hervé P, Cahn JY, Beatty PG. Graft -versus-host Disease after bone marrow transplantation from donors other than HLA-identical siblings. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft -versus-Host Disease. New York: Marcel Dekker, 1990: 452-454.
9. Bacigalupo A, Van Lint MT, Occini D, Gualandi F, Lamparelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
10. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2 receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995; 345: 1144-1146.
11. Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol 1994; 56: 203-210.
12. Cuiver KW, Ram Z, Walbridge S, Ishii H, Olfield EH, Blaese RM. In Vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
13. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci (USA) 1993; 90: 7024-7028.
14. Oldfield EH, Ram Z, Cuiver KW, Blaese RM, DeVroom HL. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 1993; 4: 39-69.
15. + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci (USA) 1992; 89: 182-186.
16. + HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. Hum Gene Ther 1992; 3: 319-338.
17. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ et al. Gene therapy for vascular smooth muscke cell proliferation after arterial injury. Science 1994; 265: 781-784.
18. Furman PA, Mc Guirt PV, Keller PM et al. Inhibition by acyclovir or cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information. Virology 1980; 102: 420.
19. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
20. Borrelli E, Heyman R, Hsi M, Evans RM. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci (USA) 1986; 85: 7572-7576.
21. Heyman RA, Borreli E, Lesley J, Anderson D, Richman DG, Baird SM et al. Thymidine kinase obliteration: creation of transgenic mice with controlled immune deficiency. Proc Natl Acad Sci (USA) 1989; 86: 2698-2702.
22. Bi WL, Parysek LM, Warnick R, Stambrook PJ. In vitro evidence that metabolic cooperation is responsable for the bystander effect observed in HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725-731.
23. Samejima Y, Meruelo D. Bystander killing induces apoptosis and is inhibited by forskolin. Gene Ther 1995; 2: 50-55.
24. Bowden RA. Infections in patients with graft -versus-host disease. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K, eds. Graft -vs-Host disease: Immunology, Pathophysiology, and Treatment. Hematology. Marcel Dekker, New York, 1990: 525.
25. Tiberghien P, Reynolds CW, Keller J, Spence S, Deschaseaux M, Certoux JM et al. Ganciclovir treatment of herpes simplex kinase-transduced primary T-lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994; 84: 1333-1341.
26. Fletcher C, Sawchuk R, Chinnock B, Miranda P, Balfour HH. Human pharmacokinetics of the antiviral drug DHPG. Clin Pharmacol Ther 1986; 40: 281-285.
27. Kernan NA, Collins NH, Juliano L, Caragena T, Dupont B, Reilly RJ. Clonable T lymphocytes in T cell depleted bone marrow transplants correlate with the development of GvHD. Blood 1990; 75: 776-780.
28. Springett GM, Moen RC, Anderson S, Blaese RM, Anderson FW. Infection efficiency of T lymphocytes with amphotropic retroviral vectors is cell cycle dependent. J Virol 1989; 63: 3865-3869.
29. Bonini C, Verzeletti S, Servida P, Rossini S, Traversari C, Ferrari G et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo immunomodulation after allo-BMT. Blood 1994; 84 (suppl 1): 110a.
30. Contassot E, Deschaseaux M, Certoux JM, Reynolds CW, Keller JR, Ruscetti FW et al. Retroviral-mediated transfer of herpes-simplex thymidine kinase (H S-tk) gene in alloreactive T-lymphocytes. Blood 1994; 84 (suppl 1): 1403a (abstract).
31. Nagler A, Ackerstein A, Or R, Drakos P, Kapelushnik Y, Mehta J et al. Adoptive immunotherapy with mismatched allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. Exp Hematol, 1992; 20: 705 (abstract).
32. Tiberghien P, Delain M, Plouvier E, Flesh M, Racadot E, Amsallem D et al. Allogeneic T-lymphocyte transfer ± IL-2 after autologous BMT for refractory hemopathies. 18th Annual Meeting of the European Bone Marrow Transplantation (EBMT), Stockholm, Sweden, May 31-June 3, (abstract), 1992.